Thomas Steiner appointed as New CEO of X1F
Hamburg, January 8, 2024 – On January 1, 2024, Thomas Steiner assumed the role of CEO at X1F. With his extensive experience and a clear vision for the future, Steiner will play an important role in the further development and continued growth of the company.

Thomas Steiner, an experienced industry expert with profound knowledge of regulated markets, was previously partner at BearingPoint, where he was responsible for the global banking and capital markets business.
In his new role at X1F, he will play a key role in the strategic direction and strengthening of the company's market position. His focus will be on developing a common vision and strengthening relationships with customers and partners.
"Our goal at X1F is to optimally align our services with the needs of our customers and to establish ourselves as a leading player in the European market for technology and management consulting. 'Ex Uno Fonte', our brand promise, stands for comprehensive digital transformation from a single source. We combine the flexibility of a medium-sized company with the expertise of a large technology consultant to offer our clients holistic, customized solutions," explains Steiner.
Richard Lustig, Investment Director at Ufenau Capital Partners, also comments positively on the acquisition of Steiner: "Since our investment in 2020, the group has grown from initially 200 employees to over 1,000 today and continued to intensify its focus on Financial Services and regulated customer industries. We are delighted to have won over Thomas Steiner for X1F and its next growth stage.”
Contacts
Hendrik Dold
Director Corporate Communications
X1F GmbH
hendrik.dold@x1f.one
Images
About X1F
The X1F Group offers technology and transformation consulting from a single source, supporting banks, insurance companies, industry and the public sector in the digital transformation with a full service offering. Under its umbrella, X1F bundles specialized, innovative and complementary services for business process and management consulting, platform integration, data analytics, artificial intelligence, security, identity & access management as well as cloud architecture and IT infrastructure. X1F as a holding company, in which funds of the Swiss private investor group Ufenau Capital Partners hold the majority stake, generates annual revenues of more than 150 million euros with its eleven corporate subsidiaries and more than 1000 employees. It offers IT solutions at 37 locations in Europe, the USA, Canada and Australia.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site29.4.2025 14:00:00 CEST | Press release
The company announced its successful approval by the U.S. Food and Drug Administration (FDA) for the manufacturing, testing and release of recombinant Cas9 nuclease from its headquarters site. Cas9 is an essential component of CRISPR-based gene editing therapies, including CASGEVY® (exagamglogene autotemcel) developed and launched by Vertex Pharmaceuticals.
Bertelsmann Stiftung: Growth and innovation as cornerstones of a strong de-mocracy and a digitally sovereign Europe29.4.2025 12:00:00 CEST | Press release
Germany should be restored to a growth path and should give new impulse to innovation, along with its European partners. Because prosperity is a significant guarantor of a stable democracy. Digital sovereignty is the anchor of a strong Europe. Germany can once again be a country of pioneering innovation and a pacesetter for the continent. For this, comprehensive modernization of the state is indispensable. The Bertelsmann Stiftung presented its proposals at the annual press conference.
Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study29.4.2025 09:00:00 CEST | Press release
Tübingen, Germany, April 29, 2025 Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.
Australia’s next government must mend structural cracks appearing in its political, economic and social foundation, report finds28.4.2025 08:33:05 CEST | Press release
Australia boasts some of the world’s most sophisticated political institutions and one of its wealthiest economies. But this veneer of success masks deeper structural issues — and a “ticking time bomb” of overreliance on extractive industries must be addressed under Australia’s next government, a new report recommends.
EOPA Best Business Product of the Year 2025 - DYMO LetraTag 200B (Source:OPI)25.4.2025 08:00:04 CEST | Press release
DYMO® LETRATAG 200B WINS PRESTIGIOUS “BUSINESS PRODUCT OF THE YEAR” AWARD - REINFORCING RISE OF SMART ORGANIZATION
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom